Matrixx Initiatives Inc. (Zicam), Scottdale, AZ 483 issued 5/28/2009, EIR signed 5/27/2005, and 483 issued 5/27/2005 (23 pages)
Similar Posts
Development of Cancer Drugs for Use in Novel Combination – Determining the Contribution of the Individual Drugs’ Effects
Development of Cancer Drugs for Use in Novel Combination – Determining the Contribution of the Individual Drugs’ EffectsPower Plus Desire contains hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Power Plus Desire, a product promoted and sold for sexual enhancement on various websites and possibly in some retail stores.CDER Conversations
Interviews with experts from FDA’s Center for Drug Evaluation and Research (CDER) on priorities, projects, and initiatives.Lincare, Inc. dba United Medical Home Infusion, Little Rock, AR. 483 Issued 08/22/2017
Lincare, Inc. dba United Medical Home Infusion, Little Rock, AR. 483 Issued 08/22/2017Task Description Request Please post to the 2017 Pharmacy Inspections and Related Records Web page
Record Date 08/22/2017
FEI Number 3011564121
Firm Name Lincare, Inc. dba United Medical Home Infusion
Record TypeC3TI Areas of Interest
C3TI’s areas of interest span drug development programs, therapeutic areas, and disciplines. Learn more.Innovative Science and Technology Approaches for New Drugs (ISTAND) Program Submission Process
The 21st Century Cures Act formally established a multi-step process for Drug Development Tools (DDT) qualification. Qualification of a DDT is for a specific context of use (COU), and the qualified DDT may be used for the COU by any person in drug or biologics development.